Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Income (2016 - 2025)

Historic Net Income for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $40.1 million.

  • Ironwood Pharmaceuticals' Net Income rose 99928.69% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.5 million, marking a year-over-year increase of 15681.0%. This contributed to the annual value of $102.8 million for FY2024, which is 10816.89% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Net Income stood at $40.1 million for Q3 2025, which was up 99928.69% from $23.6 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Net Income high stood at $391.3 million for Q2 2021, and its period low was -$1.1 billion during Q2 2023.
  • Its 5-year average for Net Income is -$22.4 million, with a median of $38.8 million in 2022.
  • In the last 5 years, Ironwood Pharmaceuticals' Net Income crashed by 303830.1% in 2023 and then skyrocketed by 284406.98% in 2025.
  • Ironwood Pharmaceuticals' Net Income (Quarter) stood at $41.4 million in 2021, then increased by 18.16% to $48.9 million in 2022, then tumbled by 567.15% to -$228.3 million in 2023, then soared by 145.63% to $104.2 million in 2024, then crashed by 61.52% to $40.1 million in 2025.
  • Its last three reported values are $40.1 million in Q3 2025, $23.6 million for Q2 2025, and -$37.4 million during Q1 2025.